-
Product Insights
NewNon-Small Cell Lung Carcinoma – Drugs In Development, 2024
Empower your strategies with our Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. “Non-small cell” refers to the way cancer cells look under a microscope. If the cells look small, the cancer is referred to as small cell lung cancer (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the...
-
Product Insights
NewSquamous Non-Small Cell Lung Carcinoma – Drugs In Development, 2024
Empower your strategies with our Squamous Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Squamous cell carcinoma (SCC) of the lung, a subtype of non-small cell lung cancer (NSCLC), typically arises centrally in the main airways like the bronchi. This cancer variant is predominantly linked to tobacco smoke, being the primary cause of cellular transformation. Smoking accounts for about 80% of lung cancer cases in men and 90% in women, with SCC showing...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rhenium-188P2045 in Squamous Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rhenium-188P2045 in Squamous Non-Small Cell Lung Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium-188P2045 in Squamous Non-Small Cell Lung Carcinoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rhenium-188P2045 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rhenium-188P2045 in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium-188P2045 in Small-Cell Lung Cancer Drug Details: Rhenium-188P2045 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adavosertib in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adavosertib in Oropharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adavosertib in Oropharyngeal Cancer Drug Details: Adavosertib (AZD-1775, MK-1775) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Luveltamab Tazevibulin in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luveltamab Tazevibulin in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luveltamab Tazevibulin in Relapsed Acute Myeloid Leukemia Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EO-4010 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EO-4010 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EO-4010 in Metastatic Colorectal Cancer Drug Details: EO-4010 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 3D-011 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 3D-011 in Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.3D-011 in Renal Cell Carcinoma Drug Details:3D-011 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rhenium-188P2045 in Squamous Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rhenium-188P2045 in Squamous Non-Small Cell Lung Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium-188P2045 in Squamous Non-Small Cell Lung Carcinoma Drug Details:...
-
Product Insights
Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. The Small-Cell Lung Cancer market research report provides comprehensive information on the therapeutics under development for SCLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its...